劳拉替尼治疗晚期间变性淋巴瘤激酶（ALK）融合阳性非小细胞肺癌的长期生存结果。 - Suppr

Suppr

超能文献

Long-term survival outcomes of lorlatinib in advanced anaplastic lymphoma kinase (ALK)-fusion positive non-small cell lung cancer.

作者信息

Morise Masahiro, Tanaka Ichidai, Ishii Makoto

机构信息

Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.

出版信息

Transl Lung Cancer Res. 2025 Aug 31;14(8):2922-2927. doi: 10.21037/tlcr-2025-564. Epub 2025 Aug 22.

DOI:10.21037/tlcr-2025-564

PMID:40948845

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12432676/

Abstract

摘要

相似文献

Long-term survival outcomes of lorlatinib in advanced anaplastic lymphoma kinase (ALK)-fusion positive non-small cell lung cancer.劳拉替尼治疗晚期间变性淋巴瘤激酶（ALK）融合阳性非小细胞肺癌的长期生存结果。

Transl Lung Cancer Res. 2025 Aug 31;14(8):2922-2927. doi: 10.21037/tlcr-2025-564. Epub 2025 Aug 22.

Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.洛拉替尼在瑞典一线治疗间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌成人患者中的成本效益分析。

Appl Health Econ Health Policy. 2023 Jul;21(4):661-672. doi: 10.1007/s40258-023-00807-7. Epub 2023 May 12.

Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.劳拉替尼、阿来替尼和布加替尼在初治/未治疗的ALK阳性晚期非小细胞肺癌中的比较：一项系统评价和网状Meta分析

J Chemother. 2022 Apr;34(2):87-96. doi: 10.1080/1120009X.2021.1937782. Epub 2021 Jun 17.

Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.一线治疗晚期间变性淋巴瘤激酶突变型非小细胞肺癌患者的疗效和安全性：系统评价和网络荟萃分析。

Cancer. 2023 Apr 15;129(8):1261-1275. doi: 10.1002/cncr.34664. Epub 2023 Feb 7.

Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).洛拉替尼与其他间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂（TKI）作为一线治疗ALK 阳性晚期非小细胞肺癌（NSCLC）的比较：系统评价和网络荟萃分析。

Lung Cancer. 2024 Nov;197:107968. doi: 10.1016/j.lungcan.2024.107968. Epub 2024 Sep 29.

Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.晚期间变性淋巴瘤激酶（<I>ALK</I>）重排非小细胞肺癌的靶向治疗。

Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2.

First-Line Alectinib, Brigatinib, and Lorlatinib for Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis.一线阿来替尼、布加替尼和劳拉替尼治疗晚期间变性淋巴瘤激酶阳性非小细胞肺癌的成本效益分析。

Value Health. 2025 Jul;28(7):1018-1028. doi: 10.1016/j.jval.2025.03.014. Epub 2025 Apr 11.

Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons.比较洛拉替尼与阿来替尼和洛拉替尼与布加替尼用于 ALK 阳性晚期/转移性 NSCLC 的疗效和安全性：匹配调整的间接比较。

Clin Lung Cancer. 2024 Nov;25(7):634-642. doi: 10.1016/j.cllc.2024.08.003. Epub 2024 Aug 13.

Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.识别晚期 ALK 阳性非小细胞肺癌一线和二线治疗中最优的 ALK 抑制剂：系统评价和网络荟萃分析。

BMC Cancer. 2024 Feb 8;24(1):186. doi: 10.1186/s12885-024-11916-4.

Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report.劳拉替尼对间变性淋巴瘤激酶融合阳性非小细胞肺癌患者软脑膜转移的长期反应：一例报告

Case Rep Oncol. 2024 Aug 27;17(1):942-949. doi: 10.1159/000540445. eCollection 2024 Jan-Dec.

本文引用的文献

Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.关键2期研究中劳拉替尼治疗ALK阳性非小细胞肺癌患者的最终总生存期和长期安全性：简要报告

J Thorac Oncol. 2025 Apr;20(4):513-520. doi: 10.1016/j.jtho.2024.11.021. Epub 2024 Nov 22.

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced -Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study.阿来替尼对比克唑替尼用于初治的亚洲晚期ALK阳性非小细胞肺癌患者：3期ALESIA研究的5年更新

JTO Clin Res Rep. 2024 Jun 27;5(9):100700. doi: 10.1016/j.jtocrr.2024.100700. eCollection 2024 Sep.

Lorlatinib Versus Crizotinib in Patients With Advanced -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.洛拉替尼对比克唑替尼用于治疗晚期 ALK 阳性非小细胞肺癌患者：III 期 CROWN 研究的 5 年结果。

J Clin Oncol. 2024 Oct 10;42(29):3400-3409. doi: 10.1200/JCO.24.00581. Epub 2024 May 31.

Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.比较间变性淋巴瘤激酶酪氨酸激酶抑制剂治疗间变性淋巴瘤激酶突变型晚期非小细胞肺癌的安全性：系统评价和网络荟萃分析。

Lung Cancer. 2023 Oct;184:107319. doi: 10.1016/j.lungcan.2023.107319. Epub 2023 Aug 7.

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.癌基因成瘾性转移性非小细胞肺癌：ESMO诊断、治疗及随访临床实践指南

Ann Oncol. 2023 Apr;34(4):339-357. doi: 10.1016/j.annonc.2022.12.009. Epub 2023 Jan 23.

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory + NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.布加替尼用于克唑替尼难治性非小细胞肺癌的长期疗效与安全性：1/2期及随机2期（ALTA）试验的最终结果

JTO Clin Res Rep. 2022 Jul 31;3(9):100385. doi: 10.1016/j.jtocrr.2022.100385. eCollection 2022 Sep.

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.III 期 J-ALEX 研究的最终总生存分析：阿来替尼对比克唑替尼用于初治的、ALK 阳性的非小细胞肺癌日本患者。

ESMO Open. 2022 Aug;7(4):100527. doi: 10.1016/j.esmoop.2022.100527. Epub 2022 Jul 14.

Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.洛拉替尼治疗间变性淋巴瘤激酶阳性肺癌和中枢神经系统特异性复发患者的 II 期研究。

JCO Precis Oncol. 2022 May;6:e2100522. doi: 10.1200/PO.21.00522.

Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).厄洛替尼联合雷莫西尤单抗与奥希替尼对比用于既往未治疗的携带EGFR L858R突变的晚期或复发性非小细胞肺癌的III期临床试验：REVOL858R（WJOG14420L）

Clin Lung Cancer. 2022 May;23(3):e257-e263. doi: 10.1016/j.cllc.2021.10.007. Epub 2021 Oct 24.

Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.布加替尼与克唑替尼用于初治的晚期ALK阳性非小细胞肺癌：3期ALTA-1L试验的最终结果

J Thorac Oncol. 2021 Dec;16(12):2091-2108. doi: 10.1016/j.jtho.2021.07.035. Epub 2021 Sep 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验